Respiratory Syncytial Virus News and Research

RSS
Quest Diagnostics Simplexa molecular test receives bronze award for best new product

Quest Diagnostics Simplexa molecular test receives bronze award for best new product

New discovery in childhood respiratory disease

New discovery in childhood respiratory disease

February is again peak time for influenza across the nation

February is again peak time for influenza across the nation

Collaborative study may lead to improved influenza vaccine and vaccines for other respiratory virus infections

Collaborative study may lead to improved influenza vaccine and vaccines for other respiratory virus infections

Immunization with VLP vaccine results in functional, protective immune responses against RSV

Immunization with VLP vaccine results in functional, protective immune responses against RSV

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

FDA clears Novavax's Phase I clinical trial to evaluate new RSV vaccine candidate

Encouraging GenVec RSV vaccine program data presented at International Respiratory Syncytial Virus Symposium

Encouraging GenVec RSV vaccine program data presented at International Respiratory Syncytial Virus Symposium

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

Bill & Melinda Gates Foundation awards $6M grant to NanoBio to develop intranasal vaccine for RSV

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

World Lung Foundation report highlights prevalence of acute respiratory infections worldwide

Idaho seeks FDA marketing clearance for FilmArray Respiratory Panel

Idaho seeks FDA marketing clearance for FilmArray Respiratory Panel

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

Alnylam third quarter revenue increases from $24.2 million to $27.7 million

New shuttlte program helps probe spaceflight-induced immune-system impairment

New shuttlte program helps probe spaceflight-induced immune-system impairment

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Alnylam Pharmaceuticals publishes ALN-RSV01 Phase IIa study results

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

Quidel receives FDA clearance for QuickVue RSV 10 immunoassay test

New blood signature test to diagnose, treat respiratory infections

New blood signature test to diagnose, treat respiratory infections

Novavax announces positive results from pre-clinical toxicology study of RSV vaccine candidate

Novavax announces positive results from pre-clinical toxicology study of RSV vaccine candidate

Alnylam second-quarter revenues increase to $26.6 million

Alnylam second-quarter revenues increase to $26.6 million

Diagnostic Hybrids receives Chinese SFDA approval for D3 Ultra DFA Respiratory Virus Screening and ID Kit

Diagnostic Hybrids receives Chinese SFDA approval for D3 Ultra DFA Respiratory Virus Screening and ID Kit

Investment report on Novavax

Investment report on Novavax